Acorda Therapeutics
 |
|
| Public | |
| Traded as |
NASDAQ: ACOR S&P 600 Component : CDG |
| Industry |
Health care Biotechnology |
| Founded | 1995 |
| Founder | Ron Cohen |
| Headquarters | Ardsley, New York, United States |
|
Key people
|
Ron Cohen (CEO) Andrew R. Blight |
| Products |
Zanaflex Ampyra Qutenza |
| Revenue |
 US$292.2 Million (FY 2011)
|
|
US$35.1 Million (FY 2011)
|
|
|
US$30.6 Million (FY 2011)
|
|
| Total assets |
US$379.5 Million (FY 2011)
|
| Total equity |
US$205.2 Million (FY 2011)
|
|
Number of employees
|
328 (February, 2012) |
| Website | Acorda.com |
Acorda Therapeutics is a biotechnology company based in Ardsley, New York, USA. The company develops drugs to improve therapies that improve neurological function in people with multiple sclerosis, spinal cord injury and other disorders of the central nervous system. Acorda manufactures and markets the drugs Zanaflex, Ampyra and Qutenza in the United States.
In September 2014 the company acquired Civitas Therapeutics for $525 million - gaining the Phase III Parkinson’s drug, CVT-301.
In January 2016, the company acquired Finnish pharmaceutical company, Biotie Therapies, for $363 million. This gave the company control over Biotes sclerosing cholangitis drug, BTT1023.
In November 2016, Acorda Therapeutics announced it was discontinuing development of dalfampridine, a drug intended for post-stroke walking difficulties, after a clinical trial failure. The discontinuation of the drug caused Acorda's shares to drop as much as 13.2%. Acorda shares have dropped 50.2% since January 2016.
As of December 31, 2013[update], the members of the board of directors of Acorda Therapeutics were: Ron Cohen, Barry Greene, Peder K. Jensen, John P. Kelley, Sandra Panem, Lorin J. Randall, Steven M. Rauscher, and Ian F. Smith.
...
Wikipedia